Theravance Biopharma (NASDAQ:TBPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Theravance received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. The company plans to launch the drug by 2018 end. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have outperformed the industry in 2018. Estimates looks stable ahead of the Q4 earnings release. Theravance has a positive record of earnings surprises in recent quarters.”

A number of other equities analysts have also weighed in on the stock. ValuEngine upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Friday, November 30th. BidaskClub raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. Leerink Swann set a $38.00 target price on shares of Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, November 7th. Cantor Fitzgerald started coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, October 23rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $43.40.

NASDAQ TBPH traded down $0.54 during mid-day trading on Monday, reaching $25.42. 1,177 shares of the stock were exchanged, compared to its average volume of 137,855. Theravance Biopharma has a 1-year low of $21.27 and a 1-year high of $35.48. The firm has a market cap of $1.44 billion, a P/E ratio of -4.66 and a beta of 1.74. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.08 and a current ratio of 3.26.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc increased its stake in Theravance Biopharma by 3.6% during the 3rd quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the period. Man Group plc purchased a new stake in Theravance Biopharma during the 3rd quarter worth $292,000. Northern Trust Corp increased its stake in Theravance Biopharma by 3.6% during the 2nd quarter. Northern Trust Corp now owns 535,284 shares of the biopharmaceutical company’s stock worth $12,140,000 after buying an additional 18,733 shares during the period. Alps Advisors Inc. increased its stake in Theravance Biopharma by 22.5% during the 3rd quarter. Alps Advisors Inc. now owns 97,513 shares of the biopharmaceutical company’s stock worth $3,186,000 after buying an additional 17,906 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in Theravance Biopharma during the 3rd quarter worth $662,000. 83.87% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Read More: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.